Oral irinotecan for treatment of pediatric solid tumors: Ready for prime time?

Pediatric Blood and Cancer

Volumn 54, Issue 5, 2010, Pages 661-662

  Wagner, Lars M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBODY; ANTIEMETIC AGENT; BEVACIZUMAB; CEFIXIME; CEPHALOSPORIN; GEFITINIB; IRINOTECAN; SOMATOMEDIN C RECEPTOR ANTIBODY; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; COLON CANCER; COST CONTROL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EWING SARCOMA; FATIGUE; FEASIBILITY STUDY; FREEZING; HEPATOBLASTOMA; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; INFECTION; LIVER FAILURE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT CANCER; RHABDOMYOSARCOMA; SALVAGE THERAPY; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; CHILD; DRUG TOXICITY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; DRUG TOXICITY; HUMANS; MAXIMUM TOLERATED DOSE;

EID: 77950465497     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22410     Document Type: Note

References (13)

1. Wagner LM. Irinotecan for treatment of childhood cancers: A promising therapeutic partner. Curr Cancer Treatment Rev (in press).
2. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
3. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007;25:362-369. (Pubitemid 350002984)
4. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:1029-1034.
5. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-570. (Pubitemid 46630418)
6. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approaches to neuroblastoma therapy consortium study. J Clin Oncol 2009;27:1290-1296.
7. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial and pharmacokinetic study of vincristine, iral irinotecan, and temozolomide (VOIT) for children with refractory silid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2009;27:523 (abstract 10017).
8. Drengler RL, Kuhn JG, Schaaf LJ, et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 1999;17:685-696. (Pubitemid 29075258)
9. Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 2008;50:201-207.
10. Bomgaars L, Kerr J, Berg S, et al. A phase II study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer 2006;46:50-55. (Pubitemid 41779317)
11. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized Phase II window study of two schedules of irinotecan and vincristine in rhabdomyosarcoma patients at first relapse/disease progression. J Clin Oncol 2008;26:542 (abstract 10013).
12. Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271-5276. (Pubitemid 46631373)
13. Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009;27:4599-4604.